Skip to Content

Skip over Generic Navigation

Skip over Subnavigations

Skip over Sitemap

May 16, 2013

Roche's obinutuzumab (GA101) significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer

Roche today announced the first results from CLL11, a phase III study of the investigational medicine GA101 which is being conducted in collaboration with the German CLL Study Group (GCLLSG). more

Media: News and Press Releases

Media Releases

May 16, 2013
Roche's obinutuzumab (GA101) significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer
May 15, 2013
FDA approves Tarceva (erlotinib) tablets and cobas EGFR Mutation Test for specific type of lung cancer
May 15, 2013
Roche to present important new data reflecting broad cancer pipeline at ASCO

See all Media Releases

Roche Stories

April 26, 2013
Drawn to Science: Sweet biologics!
April 25, 2013
Roche Turkey visits hospitals to hand presents to children with cancer
April 23, 2013
Volunteer tutors from Roche Diagnostics Indianapolis support young students

See all Roche Stories

Statements

February 26 2013
Frequently asked questions on data transparency and Tamiflu

October 26, 2012
Roche statement on EMA procedure related to alleged infringement of pharmacovigilance obligations

Services

Upcoming Events

Basel, Switzerland, July 25, 2013
Half Year Results 2013
Basel, Switzerland, October 17, 2013
Third quarter sales

© 2013 F. Hoffmann-La Roche Ltd

Legal Statement

18.05.2013

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.